Antimicrobial therapy of anaerobic infections.
D000693:Anaerobiosis; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001441:Bacteroides fragilis / Q000187:drug effects; D002511:Cephalosporins / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D003013:Clostridium / Q000187:drug effects; D004917:Erythromycin / Q000627:therapeutic use; D005673:Fusobacterium / Q000187:drug effects; D006089:Gram-Negative Anaerobic Bacteria / Q000187:drug effects*; D006801:Humans; D008034:Lincomycin / Q000627:therapeutic use; D008795:Metronidazole / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D013839:Thiamphenicol / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D008795:Metronidazole; D002981:Clindamycin; D004917:Erythromycin; D002701:Chloramphenicol; D014640:Vancomycin; D008034:Lincomycin; D013752:Tetracycline; D013839:Thiamphenicol; D012293:Rifampin